David Borg

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial

Annemieke Cats, Edwin P. M. Jansen, Nicole C.T. van Grieken et al. · The Lancet Oncology · 2018 · 562 citations

Surgical Oncology, Chemotherapy Versus Chemoradiotherapy, Gastrointestinal Oncology +8

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma

Robert Jones, Eftychia‐Eirini Psarelli, Richard Jackson et al. · JAMA Surgery · 2019 · 256 citations · Full text

Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma

Richard Fristedt, David Borg, Charlotta Hedner et al. · Journal of Gastrointestinal Oncology · 2016 · 74 citations · Full text

An immune score reflecting pro- and anti-tumoural balance of tumour microenvironment has major prognostic impact and predicts immunotherapy response in solid cancers

Artur Mezheyeuski, Max Backman, Johanna Sofia Margareta Mattsson et al. · EBioMedicine · 2023 · 72 citations · Full text